Davidson Investment Advisors Lowered Gilead Sciences (GILD) Position By $2.93 Million; Cypress Capital Group Lowered Its Abbvie (ABBV) Position

May 23, 2018 - By Adrian Mccoy

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Cypress Capital Group decreased Abbvie Inc (ABBV) stake by 3.49% reported in 2017Q4 SEC filing. Cypress Capital Group sold 5,200 shares as Abbvie Inc (ABBV)’s stock declined 6.31%. The Cypress Capital Group holds 143,887 shares with $13.92 million value, down from 149,087 last quarter. Abbvie Inc now has $166.86 billion valuation. The stock decreased 1.02% or $1.08 during the last trading session, reaching $105.15. About 5.32 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since May 23, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Davidson Investment Advisors decreased Gilead Sciences Inc (GILD) stake by 12.66% reported in 2017Q4 SEC filing. Davidson Investment Advisors sold 41,317 shares as Gilead Sciences Inc (GILD)’s stock rose 1.93%. The Davidson Investment Advisors holds 285,016 shares with $20.42M value, down from 326,333 last quarter. Gilead Sciences Inc now has $88.09 billion valuation. The stock decreased 0.12% or $0.08 during the last trading session, reaching $67.75. About 2.33 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 23, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 91 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, October 16 the stock rating was maintained by SunTrust with “Buy”. The rating was maintained by BMO Capital Markets with “Hold” on Sunday, July 30. Leerink Swann maintained the shares of ABBV in report on Monday, October 30 with “Outperform” rating. Jefferies maintained it with “Buy” rating and $10 target in Friday, September 15 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Hold” rating by BMO Capital Markets on Wednesday, April 19. Bank of America maintained AbbVie Inc. (NYSE:ABBV) on Monday, March 26 with “Hold” rating. As per Thursday, September 28, the company rating was upgraded by Deutsche Bank. Goldman Sachs maintained it with “Buy” rating and $80 target in Friday, March 10 report. The firm has “Buy” rating given on Tuesday, December 5 by Leerink Swann. The stock of AbbVie Inc. (NYSE:ABBV) has “Underperform” rating given on Tuesday, January 30 by BMO Capital Markets.

Since December 14, 2017, it had 0 insider buys, and 11 selling transactions for $47.70 million activity. Shares for $14.07M were sold by Schumacher Laura J on Thursday, December 14. On Wednesday, February 28 the insider GONZALEZ RICHARD A sold $976,084. Another trade for 70,928 shares valued at $8.31 million was made by CHASE WILLIAM J on Wednesday, February 28. Shares for $2.15 million were sold by RICHMOND TIMOTHY J.. The insider ALBAN CARLOS sold $9.57 million. On Wednesday, February 28 SALEKI-GERHARDT AZITA sold $157,458 worth of AbbVie Inc. (NYSE:ABBV) or 1,337 shares. Shares for $311,684 were sold by SEVERINO MICHAEL.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Streetinsider.com which released: “Abbvie (ABBV) PT Lowered to $78 at BMO Capital” on May 23, 2018, also Seekingalpha.com with their article: “AbbVie: Can Mylan Pull Off A Humira Biosimilar?” published on May 01, 2018, 247Wallst.com published: “Why One Old Stock Buyback Trick Is Working So Well for AbbVie” on May 01, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “AbbVie Is Still A One-Trick Pony” published on April 26, 2018 as well as Investorplace.com‘s news article titled: “3 Stocks to Buy to Find Gains in Today’s Market” with publication date: May 22, 2018.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $3.13 billion for 13.34 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.05, from 0.85 in 2017Q3. It fall, as 42 investors sold ABBV shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. The Missouri-based Smith Moore Com has invested 0.79% in AbbVie Inc. (NYSE:ABBV). Moreover, Stonebridge Cap Mgmt Inc has 0.43% invested in AbbVie Inc. (NYSE:ABBV). Mutual Federation Of Agricultural Cooperatives has 24,000 shares. Gamble Jones Inv Counsel invested in 1.53% or 166,676 shares. Nomura Inc accumulated 0.02% or 121,278 shares. Hm Payson And reported 1.32% of its portfolio in AbbVie Inc. (NYSE:ABBV). Chase Inv Counsel Corp, Virginia-based fund reported 2,122 shares. Farmers Bancshares owns 7,438 shares. 22,486 were reported by Montrusco Bolton Invs Incorporated. Usa Fincl Portformulas Corp has invested 0.9% of its portfolio in AbbVie Inc. (NYSE:ABBV). 4,398 were accumulated by Heritage Wealth. Wright Investors owns 54,653 shares for 1.77% of their portfolio. Stevens First Principles Inv Advisors holds 0% or 95 shares in its portfolio. Hayek Kallen Mngmt reported 37,844 shares stake. Plancorp holds 0.58% or 18,344 shares in its portfolio.

Davidson Investment Advisors increased Tableau Software Inc (NYSE:DATA) stake by 27,760 shares to 97,075 valued at $6.72M in 2017Q4. It also upped Cisco Sys Inc (NASDAQ:CSCO) stake by 75,282 shares and now owns 713,659 shares. Baker Hughes A Ge Co was raised too.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It dropped, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Van Hulzen Asset Mngmt Ltd Llc invested in 14,627 shares. Lafleur & Godfrey Ltd Liability holds 63,632 shares. Cibc Ww Markets reported 654,161 shares. 13,014 are held by Prelude Mgmt Ltd. Trust Of Vermont stated it has 41,643 shares. British Columbia Inv Management holds 742,048 shares or 0.37% of its portfolio. State Of New Jersey Common Pension Fund D has 1.57M shares for 0.42% of their portfolio. Contrarius Investment Management has invested 0.75% in Gilead Sciences, Inc. (NASDAQ:GILD). Rench Wealth Management Incorporated holds 1.5% or 32,229 shares in its portfolio. Aviance Capital Partners Ltd Company stated it has 0.42% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Dana Advisors owns 26,851 shares or 0.08% of their US portfolio. Tru Co Of Toledo Na Oh accumulated 23,439 shares or 0.42% of the stock. 108,940 are held by Badgley Phelps Bell. Hillsdale Invest Inc accumulated 5,510 shares. Trillium Asset Ltd Com holds 60,968 shares.

Since January 2, 2018, it had 0 buys, and 22 sales for $44.80 million activity. Cogan John Francis sold $472,065 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, March 12. 25,000 shares valued at $2.09 million were sold by Alton Gregg H on Thursday, February 1. Meyers James R also sold $8.02 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. Shares for $4.18 million were sold by MARTIN JOHN C. The insider WILSON GAYLE E sold $4.68 million. Shares for $401,566 were sold by Washington Robin L on Wednesday, February 21.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Bizjournals.com which released: “He helped Gilead score billions from HIV, hepatitis C drugs — now he’s building a cancer fighter” on May 23, 2018, also Seekingalpha.com with their article: “Gilead: Where’s The Next Catalyst?” published on May 18, 2018, Nasdaq.com published: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” on May 22, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: I’m Thankful That I Sold” published on May 07, 2018 as well as Streetinsider.com‘s news article titled: “Potenital Gilead (GILD) Takeover of TESARO (TSRO) Would Make Sense – Bloomberg, Citing Wedbush Analyst” with publication date: May 22, 2018.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 earnings per share, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86 billion for 11.84 P/E if the $1.43 EPS becomes a reality. After $1.37 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, August 28 by Maxim Group. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, October 5 by Jefferies. The rating was downgraded by Maxim Group on Friday, April 29 to “Hold”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Mizuho on Sunday, October 29. The company was maintained on Tuesday, March 15 by Jefferies. The stock has “Hold” rating by Maxim Group on Tuesday, May 30. Oppenheimer maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, October 20 with “Outperform” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Thursday, August 31 by William Blair. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Needham on Wednesday, July 29. The firm has “Neutral” rating given on Friday, December 18 by Atlantic Securities.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>